Transforming Oligonucleotide Manufactuing

In the latest issue of Chemistry Today, Andrew Livingston and Katie Murray discuss the challenges involved with oligonucleotide manufacturing, and the role Nanostar Sieving can play in overcoming them.

Oligonucleotides, which have already shown success in the treatment of rare diseases, are now being used to treat conditions with much larger patient populations. However, limitations associated with the current state-of-the-art solid-phase manufacturing technology – namely high costs and low capacity – inhibit their true potential. Despite this, oligonucleotide-based drugs are still moving through the R&D pipeline, but their progress will be hindered without an overhaul of the current manufacturing process. An exciting academic, government and industry collaboration is investigating the potential of a novel liquid-phase synthesis technique. This technique – referred to as Nanostar Sieving – circumvents many of the limitations associated with solid-phase oligonucleotide manufacturing, offering a more cost-effective and environmentally sustainable method of manufacturing oligonucleotides at a larger scale.

Read the full article here: